Join Dr. William Prueitt, Director of Ketamine Treatment Program at Silver Hill and Sarah Pauker, LPC, Clinical Supervisor at Anxiety Institute, for a compelling webinar examining the innovative use of ketamine in addressing severe, treatment-resistant depression.
Discover cutting-edge insights into its mechanisms of action, clinical utility, and practical implementation in therapeutic settings.
Ketamine, once primarily known as an anesthetic, has emerged as a groundbreaking intervention for treatment-resistant depression. This session will provide mental health professionals with an evidence-based exploration of its benefits, potential risks, and strategies for determining patient suitability.
Through real-world case studies and expert perspectives, participants will gain a deeper understanding of integrating ketamine into clinical practice to optimize treatment outcomes. The webinar will conclude with actionable takeaways and a Q&A session to address participant questions.